AbbVie (NYSE:ABBV) AbbVie is a drug company with a strong exposure to immunology and oncology. The company’s top drug, Humira, represents close to half of the company’s current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women’s health. Open 219.020 Close 217.720 Vol / Avg. 7.621M / 6.693M Mkt Cap 385.473B Day Range 214.900 - 219.600 52 Wk Range 181.730 - 244.810 Immix Biopharma (NASDAQ:IMMX) Immix Biopharma Inc is a clinical-stage biopharmaceutical company developing Tissue-Specific Therapeutics in oncology and inflammation. Its product candidate drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Open 8.820 Close 9.000 Vol / Avg. 964.011K / 941.631K Mkt Cap 636.139M Day Range 8.535 - 9.060 52 Wk Range 1.870 - 11.610 Johnson & Johnson (NYSE:JNJ) Johnson & Johnson is the world’s largest and most diverse healthcare firm.…